A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia

Inclusion Criteria:

• Healthcare professionals working only in Saudi Arabia AND

• Prescribers of Depakine® (sodium valiporate) at least once in the six months leadingup to survey completion OR

• Obstetricians/Gynecologists who consulted at least one women of childbearingpotential treated with Depakine® (sodium valproate) in the six months leading up tosurvey completion OR

• Pharmacists who have dispensed Depakine® (sodium valproate) in the six monthsleading up to survey completion

Exclusion Criteria:

• Healthcare professionals who may have conflicts of interest with the survey (i.e.employed by regulatory bodies or pharmaceutical companies)

• Healthcare professionals (or with a relative) involved in valproate-related lawsuitsor associations for victims of valproate syndrome

• Healthcare professionals who are not prescribing Depakine® (sodium valproate),except for obstetricians/gynecologists (who do not prescribe Depakine® [sodiumvalproate])

• Healthcare professionals having started to prescribe or dispense Depakine® (sodiumvalproate) earlier than six months before survey completion

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.